AQR Capital Management
NMTC icon

AQR Capital Management’s NeuroOne Medical Technologies NMTC Stock Holding History

AQR Capital Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.09K Sell
1,737
-2
-0.1% -$10 ﹤0.01% 3736
2025
Q4 		$7.91K Sell
1,739
-2
-0.1% -$9 ﹤0.01% 3557
2025
Q3 		$9.28K Sell
1,741
-4
-0.2% -$20 ﹤0.01% 3455
2025
Q2 		$7.1K Buy
+1,745
New +$6.44K ﹤0.01% 3289

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

AQR Capital Management's NMTC Position: Q1 2026 in Review

AQR Capital Management reduced its NeuroOne Medical Technologies (NMTC) stake by 0.12% in Q1 2026, selling an estimated $10 and leaving 1,737 shares worth $8.09K. The position accounts for ﹤0.01% of the portfolio, ranked #3736.

AQR Capital Management first reported a position in NMTC in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.28K in Q3 2025. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • AQR Capital Management held 1,737 shares of NeuroOne Medical Technologies worth $8.09K as of Q1 2026.
  • AQR Capital Management sold 2 NeuroOne Medical Technologies shares in Q1 2026, an estimated $10.
  • NeuroOne Medical Technologies made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3736 holding.
  • AQR Capital Management first reported a position in NeuroOne Medical Technologies in Q2 2025 and has held it in 4 quarters since.
  • AQR Capital Management's NeuroOne Medical Technologies position peaked at $9.28K in Q3 2025.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.